Erectile function preservation after radiotherapy using a dose-optimization approach on sexual structures for localized prostate cancer

IF 1.5 4区 医学 Q4 ONCOLOGY Cancer Radiotherapie Pub Date : 2024-04-01 DOI:10.1016/j.canrad.2023.08.010
A. Chardon , C. Udrescu , A. Beneux , A. Ruffion , S. Horn , A. Lapierre , O. Chapet
{"title":"Erectile function preservation after radiotherapy using a dose-optimization approach on sexual structures for localized prostate cancer","authors":"A. Chardon ,&nbsp;C. Udrescu ,&nbsp;A. Beneux ,&nbsp;A. Ruffion ,&nbsp;S. Horn ,&nbsp;A. Lapierre ,&nbsp;O. Chapet","doi":"10.1016/j.canrad.2023.08.010","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>Erectile function preservation is an important quality of life factor in patients treated for prostate cancer. A dose-optimization approach on sexual structures was developed and evaluated to limit erectile dysfunction after radiotherapy.</p></div><div><h3>Materials and methods</h3><p>Twenty-three men with localized prostate cancer and no erectile dysfunction were enrolled in the study. All patients received a prescription dose between 76 and 78<!--> <!-->Gy. Computed tomography/magnetic resonance image registration was used to delineate the prostatic volume and the sexual structures: internal pudendal arteries (IPA), penile bulb and corpus cavernosum. Erectile function was evaluated using the 5-items International Index of Erectile Function (IIEF-5) score every 6 months during the 2 years after radiotherapy and once a year afterwards. No erectile dysfunction, mild erectile dysfunction and severe erectile dysfunction were defined if the IIEF-5 scores were 20–25, 17–19 and &lt; 17, respectively.</p></div><div><h3>Results</h3><p>The mean follow-up was 4.5 years. The mean age of the patients was 66.3 years. At 2 years, 67% of the patients had no erectile dysfunction, 11% had mild erectile dysfunction and 22% had severe erectile dysfunction. No significant difference was found between the patients with and without erectile dysfunction (IIEF-5<!--> <!-->≥<!--> <!-->20 and IIEF-5<!--> <!-->&lt;<!--> <!-->20, respectively) for any of the parameters: dosimetric values (internal pudendal arteries, penile bulb, corpus cavernosum), age, comorbidity and smoking status. The biochemical-relapse free survival was 100% at 2 years.</p></div><div><h3>Conclusion</h3><p>This approach with dose-optimization on sexual structures for localized prostate cancer found excellent results on erectile function preservation after radiotherapy, with 78% of the patients with no or mild erectile dysfunction at 2 years.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Radiotherapie","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1278321824000295","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

Erectile function preservation is an important quality of life factor in patients treated for prostate cancer. A dose-optimization approach on sexual structures was developed and evaluated to limit erectile dysfunction after radiotherapy.

Materials and methods

Twenty-three men with localized prostate cancer and no erectile dysfunction were enrolled in the study. All patients received a prescription dose between 76 and 78 Gy. Computed tomography/magnetic resonance image registration was used to delineate the prostatic volume and the sexual structures: internal pudendal arteries (IPA), penile bulb and corpus cavernosum. Erectile function was evaluated using the 5-items International Index of Erectile Function (IIEF-5) score every 6 months during the 2 years after radiotherapy and once a year afterwards. No erectile dysfunction, mild erectile dysfunction and severe erectile dysfunction were defined if the IIEF-5 scores were 20–25, 17–19 and < 17, respectively.

Results

The mean follow-up was 4.5 years. The mean age of the patients was 66.3 years. At 2 years, 67% of the patients had no erectile dysfunction, 11% had mild erectile dysfunction and 22% had severe erectile dysfunction. No significant difference was found between the patients with and without erectile dysfunction (IIEF-5  20 and IIEF-5 < 20, respectively) for any of the parameters: dosimetric values (internal pudendal arteries, penile bulb, corpus cavernosum), age, comorbidity and smoking status. The biochemical-relapse free survival was 100% at 2 years.

Conclusion

This approach with dose-optimization on sexual structures for localized prostate cancer found excellent results on erectile function preservation after radiotherapy, with 78% of the patients with no or mild erectile dysfunction at 2 years.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
采用剂量优化方法对局部前列腺癌的性结构进行放疗后保留勃起功能
目的 保护勃起功能是前列腺癌患者生活质量的一个重要因素。为了限制放疗后的勃起功能障碍,我们开发并评估了一种性结构剂量优化方法。所有患者的处方剂量都在 76 到 78 Gy 之间。计算机断层扫描/磁共振图像登记用于划定前列腺体积和性结构:阴茎内动脉(IPA)、阴茎球和海绵体。在放疗后的两年内,每六个月使用5项国际勃起功能指数(IIEF-5)评分对勃起功能进行评估,之后每年评估一次。如果 IIEF-5 评分分别为 20-25、17-19 和 < 17,则定义为无勃起功能障碍、轻度勃起功能障碍和重度勃起功能障碍。患者的平均年龄为 66.3 岁。2年后,67%的患者无勃起功能障碍,11%的患者有轻度勃起功能障碍,22%的患者有重度勃起功能障碍。有勃起功能障碍和无勃起功能障碍的患者(IIEF-5 ≥ 20 和 IIEF-5 < 20)在剂量值(阴茎内动脉、阴茎球部、海绵体)、年龄、合并症和吸烟状况等参数方面均无明显差异。结论这种对局部前列腺癌性结构进行剂量优化的方法在放疗后保留勃起功能方面效果极佳,78% 的患者在 2 年后无勃起功能障碍或出现轻度勃起功能障碍。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cancer Radiotherapie
Cancer Radiotherapie 医学-核医学
CiteScore
2.20
自引率
23.10%
发文量
129
审稿时长
63 days
期刊介绍: Cancer/radiothérapie se veut d''abord et avant tout un organe francophone de publication des travaux de recherche en radiothérapie. La revue a pour objectif de diffuser les informations majeures sur les travaux de recherche en cancérologie et tout ce qui touche de près ou de loin au traitement du cancer par les radiations : technologie, radiophysique, radiobiologie et radiothérapie clinique.
期刊最新文献
Editorial Board Committee of the new positions of the Société française de radiothérapie oncologique: Toward an advanced practice master in radiotherapy Practice-changing trials on breast cancer Personalizing radiotherapy with adaptive radiotherapy: Interest and challenges Preoperative stereotactic radiotherapy for the management of brain metastases
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1